NICE keeps the UK out of step with US and EU on anti-amyloid coverage

The UK regulatory and reimbursement story for anti-amyloid antibodies separates a yes-on-approval from a no-on-funding in unusually clean terms. MHRA authorization established that the drugs meet the regulatory standard. NICE's subsequent assessment concluded that the cost-effectiveness ratio at the manufacturer's price did not meet the threshold for routine NHS funding.

The effect is that NHS-funded access to anti-amyloid therapy in the UK is meaningfully constrained, even where individual clinicians and patients would otherwise pursue treatment. Routes that remain include private payment and limited research-based pathways. The downstream operational effect - on infusion capacity, on MRI surveillance demand, on specialist workflow - is therefore much smaller in the UK than it is in the US or in EU markets that funded broader access.

Two threads are worth following:

• Whether subsequent NICE reviews - triggered by price changes, by new evidence, or by post-marketing safety and effectiveness data - alter the position.
• Whether the UK case becomes a reference point for cost-effectiveness conversations in other publicly funded systems with similar threshold frameworks.

The broader signal is that regulatory approval has become a smaller fraction of what determines real-world access. Reimbursement decisions, infrastructure capacity, and pricing dynamics increasingly carry more weight.